Figure 4. HMGA2 short interfering RNA treatment decreases the proliferation of RB (Y79, WERI Rb1) cells. The Y79 cells were treated with high mobility group A2 (HMGA2) short interfering (si)RNA, and the cell proliferation was assessed at 24, 48, and 72 h using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The cell viability decreased to 81.7%, 67.5%, and 45.5% in the Y79 cell line, and to 75.4%, 69.4%, and 49.9% in the WERI Rb1 cell line when compared to Y79 cells that were not treated with siRNA. The error bars represent the standard deviation of triplicate values.